Stephen Hanauer

There are multiple new biologic agents that have been approved for the management of IBD over the past few years. In addition, high quality randomized controlled trials have examined optimization of these treatments through therapeutic drug monitoring…

BACKGROUND: After successful induction, a subset of patients with Crohn’s disease (CD) experience a secondary loss of response (LoR) to ustekinumab (UST) maintenance therapy. Dose intensification may assist in regaining response…

SOCIETY: DDW

1) Examine clinical and objective treatment goals 2) Follow the journeys of patients with moderate to severe CD 3) Review the safety and efficacy for patients with moderate to severe CD Sponsored by AbbVie

The landscape of treatment for IBD has evolved significantly over the past two decades. This session will examine advances in our understanding of disease pathogenesis and review treatment paradigm changes…